BioSpace News Archive

Zivo Bioscience, Inc. announces it has uplisted the trading of shares of its common stock from the OTC ® Pink Market to the OTCQB ® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024.

Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug

TransCode Therapeutics, Inc. today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases.

CytoDyn Inc. announced today that Dr. Jacob Lalezari, formerly interim CEO, was appointed to the CEO role, effective January 26, 2024.

Ascendis Pharma A/S announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.

SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene.

RenovoRx, Inc. today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company’s founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey.

Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections.

Rise Therapeutics today announced that it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.